Jennison Associates LLC lowered its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 89.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,238 shares of the company's stock after selling 1,704,207 shares during the quarter. Jennison Associates LLC's holdings in Sanofi were worth $9,657,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the business. Synergy Asset Management LLC acquired a new position in Sanofi in the fourth quarter valued at about $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi in the 3rd quarter worth $29,000. Concord Wealth Partners grew its holdings in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after buying an additional 363 shares in the last quarter. Fortitude Family Office LLC grew its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after acquiring an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after buying an additional 313 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $60.00.
View Our Latest Stock Analysis on Sanofi
Shares of Sanofi stock opened at $53.50 on Thursday. The stock has a market capitalization of $135.77 billion, a PE ratio of 21.49, a price-to-earnings-growth ratio of 1.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a 50 day moving average price of $49.54 and a two-hundred day moving average price of $52.35.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, equities analysts anticipate that Sanofi will post 4.34 earnings per share for the current fiscal year.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.